|
KMID : 1197720160090030136
|
|
대한파킨슨병 및 이상운동질환 학회지
2016 Volume.9 No. 3 p.136 ~ p.143
|
|
|
Applications of CRISPR/Cas9 for Gene Editing in Hereditary Movement Disorders
|
|
Im Woo-Seok
Moon Jang-Sup
Kim Man-Ho
|
|
|
Abstract
|
|
|
|
Gene therapy is a potential therapeutic strategy for treating hereditary movement disorders, including hereditary ataxia, dystonia, Huntington’s disease, and Parkinson’s disease. Genome editing is a type of genetic engineering in which DNA is inserted, deleted or replaced in the genome using modified nucleases. Recently, clustered regularly interspaced short palindromic repeat/CRISPR associated protein 9 (CRISPR/Cas9) has been used as an essential tool in biotechnology. Cas9 is an RNA-guided DNA endonuclease enzyme that was originally associated with the adaptive immune system of Streptococcus pyogenes and is now being utilized as a genome editing tool to induce double strand breaks in DNA. CRISPR/Cas9 has advantages in terms of clinical applicability over other genome editing technologies such as zinc-finger nucleases and transcription activator-like effector nucleases because of easy in vivo delivery. Here, we review and discuss the applicability of CRISPR/Cas9 to preclinical studies or gene therapy in hereditary movement disorders.
|
|
|
KEYWORD
|
|
|
CRISPR/Cas9, gene editing, gene therapy, hereditary movement disorders
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
|
|